Semax raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-07-17 and is reviewed periodically as new material appears.
Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design combines the ACTH(4-7) core fragment with a C-terminal Pro-Gly-Pro extension, a modification intended to improve stability and prolong activity. The molecule is hydrophilic, carries no lipid chains or glycosylation, and has a theoretical mass just over 810 daltons in its free form. All seven residues are proteinogenic amino acids, so no non-natural building blocks appear in the backbone. A free N-terminal methionine and C-terminal proline define the unmodified parent peptide.
The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.
Development of the compound took place in the Soviet Union during the 1980s, largely through peptide research groups affiliated with the Shemyakin-Ovchinnikov Institute and Moscow State University. Investigators screened fragments of adrenocorticotropic hormone for activity on the central nervous system while attempting to separate cognitive effects from hormonal ones. The shortened sequence was selected because it retained behavioral activity in animal models without stimulating corticosteroid release. Early publications described the molecule as an ACTH(4-10) analog.
Published research on this peptide originates mainly from Russian laboratories, and the wider international literature is comparatively thin. Studies have used rodent models of stroke, hypoxia, and memory tasks, with a smaller number of human trials reported. Reported outcomes include changes in attention and memory measures, along with effects on neurotrophic factor expression in some experiments. Small sample sizes, inconsistent dosing protocols, and limited independent replication are widely noted limitations, so the strength of the clinical evidence remains an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | ACTH(4-7) analogue |
| Sequence | Met-Glu-His-Phe-Pro-Gly-Pro | Free N terminus, unmodified side chains |
| Molecular weight | 813.9 Da | Free base; salt forms differ |
| Appearance | White to off-white powder | Lyophilised solid |
| Solubility | Freely soluble in water | Hydrophilic; polar solvents preferred |
The compound is registered in Russia as a pharmaceutical product, most commonly formulated as a nasal solution, and has been used in that setting since the 1990s. Outside that jurisdiction it is generally handled as a research chemical rather than an approved medicine. Regulatory status therefore differs sharply between countries, and material sold internationally may not correspond to the Russian pharmaceutical formulation. Documentation with commercial samples is typically limited to a certificate of analysis covering purity and identity, not clinical status or local legal classification.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It corresponds to the ACTH(4-7) fragment extended at the C-terminus by a Pro-Gly-Pro tripeptide, an addition intended to slow enzymatic breakdown. The molecular formula is C37H51N9O10S and the molecular mass is approximately 814 daltons. In the literature it is often described as an ACTH(4-10) analog, although that label reflects a naming convention as much as a precise structural relationship. The compound was developed in Russia and remains most closely associated with that research tradition.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its chain combines the first seven residues of corticotropin with a C-terminal proline-glycine-proline extension, a modification intended to slow enzymatic breakdown. The free peptide has a molecular mass near 813.9 daltons. It belongs to the class of ACTH-derived fragments studied for central nervous system activity rather than for adrenal steroid stimulation. This structural relationship to a natural hormone fragment is the usual starting point for describing the compound in the literature.
Development took place during the 1980s at institutes of the Russian Academy of Sciences, where peptide fragments of ACTH were screened for cognitive and neuroprotective effects. The compound received regulatory approval in Russia as a nasal preparation, marketed for conditions such as ischemic stroke, transient ischemic attacks, and optic nerve disorders. Registration in other countries has not followed. Most published clinical reports originate from a small number of Russian research groups, and independent replication outside that setting remains limited. The regulatory status therefore differs sharply between Russia and the rest of the world.
They launched this new device in the UK in 2008 under their Gamucci brand and the design is now widely adopted by most "cigalike" brands. Other users tinkered with various parts to produce more satisfactory homemade devices, and the hobby of "modding" was born. The first mod to replace the e-cigarette's case to accommodate a longer-lasting battery, dubbed the "screwdriver", was developed by Ted and Matt Rogers in 2008. This device generated a lot of interest, as it let the user to vape for hours at one time. Other enthusiasts built their own mods to improve functionality or aesthetics. When pictures of mods appeared at online vaping forums many people wanted them, so some mod makers produced more for sale. These mods led to demand for customizable e-cigarettes, prompting manufacturers to produce devices with interchangeable components that could be selected by the user. In 2009, Joyetech developed the eGo series which offered the power of the screwdriver model and a user-activated switch to a wide market. The clearomizer was invented in 2009. Originating from the cartomizer design, it contained the wicking material, an e-liquid chamber, and an atomizer coil within a single clear component. The clearomizer allows the user to monitor the liquid level in the device. Soon after the clearomizer reached the market, replaceable atomizer coils and variable voltage batteries were introduced. Clearomizers and eGo batteries became the best-selling customizable e-cigarette components in early 2012.
All chordates are deuterostomes. Which means, during embryonic development, the anus forms before the mouth does. All chordates are based on a bilateral body plan. All chordates are coelomates, and have a fluid-filled body cavity (coelom) with a complete serosal lining derived from mesoderm called mesothelium (see Brusca and Brusca).
Wolverine is one of the few X-Men characters appearing in nearly every media adaptation of the X-Men franchise, including the 20th Century Fox X-Men films, television, computer and video games. Australian actor Hugh Jackman portrayed Wolverine in the X-Men films, beginning in X-Men (2000). He reprised the role in X2 (2003), X-Men: The Last Stand (2006), X-Men Origins: Wolverine (2009), X-Men: First Class (2011), The Wolverine (2013), X-Men: Days of Future Past (2014), X-Men: Apocalypse (2016), Logan (2017), and Deadpool & Wolverine (2024). Logan received praise from critics, and a nomination for an Academy Award for Best Adapted Screenplay in 2018; it was the first superhero film to be nominated in the category. Deadpool & Wolverine became the highest grossing R-rated film ever made. Wolverine's first animated appearance was in Spider-Man and His Amazing Friends (1981). He has since been featured in a starring capacity in X-Men: The Animated Series (1992–1997), X-Men: Evolution (2000–2003), Wolverine and the X-Men (2009), Marvel Anime: Wolverine and Marvel Anime: X-Men (both 2011), and X-Men '97 (2024–present). The 1992-97 animated series was particularly significant in introducing Wolverine to a mass popular audience. At its peak, in 1994, it was watched by 23 million households weekly, the highest rated show on Fox Kids. Cal Dodd voices the character in X-Men: The Animated Series and its revival X-Men '97; producers suggested that Dodd base his vocal performance on Clint Eastwood.
The community centre includes a swimming pool (the only public one in the islands), a sports centre, and a school. A grass football pitch is located by the community centre. A separate building houses the college of further education and the library. A new sports centre is under construction to the south of the town centre, next to a newly-laid floodlit all-weather pitch. Stanley Racecourse, located on the west side of Stanley, holds a two-day horse racing meeting every year on 26 and 27 December. The Christmas races have been held here for over 100 years. Stanley Golf Course has an 18-hole course and a club house. It is also located to the west of Stanley. King Edward VII Memorial Hospital is the islands' main hospital, with doctors' practice and surgery, radiology department, dental surgery and emergency facilities. The Port Stanley Airport operates internal flights, and scheduled international passenger flights operate from the RAF Mount Pleasant military airbase. Stanley is also home to the Falkland Islands Radio Station (FIRS), the Stanley office of the British Antarctic Survey, and the office of the weekly Penguin News newspaper.
Sources: en.wikipedia.org
Bacterial culture of H. influenzae is performed on agar plates. The strongest growth is seen on chocolate agar at 37 °C in a CO2-enriched incubator. The ideal CO2 concentration for the culture is ~5%. However adequate growth is often seen on brain-heart infusion agar supplemented with hemin and nicotinamide adenine dinucleotide (NAD) Colonies of H. influenzae appear as convex, smooth, pale, grey, or transparent colonies with a mild odor. H. influenzae will only grow on blood agar if other bacteria are present to release these factors from the red blood cells, forming 'satellite' colonies around these bacteria. For example, H. influenzae will grow in the hemolytic zone of Staphylococcus aureus on blood agar plates; the hemolysis of cells by S. aureus releases NAD which is needed for its growth. H. influenzae will not grow outside the hemolytic zone of S. aureus due to the lack of nutrients in these areas.
== Education == Pediatric dentistry is one of the ten dental specialties recognized by American Dental Association. Other specialties include dental public health, endodontics, oral and maxillofacial pathology, oral and maxillofacial radiology, oral and maxillofacial surgery, orthodontics and dentofacial orthopedics, periodontics, and prosthodontics. The first step would be obtaining a college degree in biomedical science, health science, or social science as long as all biomedical course pre-requisites are met courses. While in college, one can explore the profession by shadowing in a pediatric dental office or children's hospital, or working on academic research that studies oral health of children. Second step would be attending a dental school that involves four years of education and training. One can graduate with Doctor of Dental Surgery (DDS) or Doctor of Dental Medicine (DMD). Both degrees are equivalent and people receive the same training as required by the CODA (Commission on Dental Accreditation). During the first two years of dental school, dental students will take didactic classes on biomedical sciences and hands on classes to learn technical procedures in a pre-clinical laboratory setting. Third and fourth years of dental school focus on clinical care under the supervision of attending faculty who are licensed dentists. Before graduating, all dental students must pass National Board Dental Examination part I and part II, as well as clinical skill exams (e.g., ADEX, WREB, etc) to become a licensed general dentist.
== Research == Current research in regenerative medicine spans a continuous spectrum from fundamental cell biology to clinical translational engineering, focusing on deciphering and manipulating the signaling pathways that govern tissue morphogenesis, cellular differentiation, and scarless wound healing. Rather than merely managing chronic symptoms, active laboratory investigations aim to understand why adult mammalian tissues lose the regenerative capacities inherent in lower vertebrates and human embryonic states. Research strategies are broadly categorized into three interdependent vectors: cell-based therapies, which isolate and direct stem cell fates; biomaterial design, which engineers bioactive scaffolds to mimic the native extracellular matrix; and the delivery of localized biochemical cues, such as growth factors and gene-editing complexes, to orchestrate endogenous tissue repair. A major bottleneck in ongoing research is solving the scalability of functional vascularization, as complex engineered tissues cannot survive past the limits of oxygen diffusion without an integrated capillary network.
== Neutrophil-activating peptide 2 == Neutrophil-activating peptide 2 (NAP-2) is a chemokine that corresponds to positions 59-128 of PPBP. NAP-2 activates and attracts neutrophils through interaction with the receptors CXCR1 and CXCR2. There are also shorter (and longer) versions of this peptide with similar effects, with NAP-2(1-63) (corresponding to positions 59-121 of PPBP) being the most potent.
The diagram shows a simplified decay scheme of 60Co and 60mCo. The main β-decay transitions are shown. The probability for population of the middle energy level of 2.1 MeV by β-decay is only 0.0022%, with a β-energy of 0.67 MeV. Transitions between the three levels generate six different gamma-ray frequencies. In the diagram the two important ones are marked. Internal conversion is not significant. The half-value and 1/10th value layer thickness for shielding against this isotope's radiations has been determined for different materials:
Sources: en.wikipedia.org
It is a synthetic seven-amino-acid peptide built from the ACTH(4-7) sequence plus a Pro-Gly-Pro tail. It belongs to the family of short ACTH fragments studied for nervous-system effects. Its backbone contains only standard amino acids.
It contains the 4-7 fragment of adrenocorticotropic hormone extended at the C terminus. That truncation removes the region associated with steroidogenic activity. The design intent was to keep neurotrophic properties while avoiding full hormonal effects.
No natural source of the intact heptapeptide is known. It is produced by solid-phase peptide synthesis. Some related ACTH fragments arise as hormone processing products, but the Pro-Gly-Pro extension is a designed addition rather than a natural sequence.
It is a synthetic peptide of seven amino acids. Its backbone corresponds to a fragment of adrenocorticotropic hormone extended at the carboxyl end. The material is distributed as a lyophilized solid for laboratory use.